Skip to main content

MOTS-c vs Pinealon

Both MOTS-c and Pinealon are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

Pinealon

Evidence C

Pinealon (EDR)

A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.

View full Pinealon profile →

Side-by-Side

AttributeMOTS-cPinealon
Evidence GradeBC
FDA StatusNot FDA-approved — research peptide; multiple early-phase clinical trialsNot FDA-approved — Russian-origin research peptide
Typical Dose5–10 mg, 2–3 times weekly (subcutaneous)5–10 mg daily for 10–20 days (subcutaneous, cycled)
Clinics Indexed229
Categoriesmetabolic, longevitycognitive, longevity

Key reported benefits — MOTS-c

  • Insulin sensitivity
  • Exercise capacity
  • Metabolic flexibility

Key reported benefits — Pinealon

  • Cognitive function (preclinical)
  • Reduced oxidative damage
  • Sleep/circadian effects

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons